Drug Fix: Regulatory Nationalism And US FDA’s IND Reforms

Pink Sheet Executive Editor Derrick Gingery, Senior Editor Sue Sutter and Editor-in-Chief Nielsen Hobbs discuss the impact of nationalism on the regulatory process, which entered the fray once again when news of a potential AstraZeneca-Bristol Myers Squibb merger broke (:58), as well as the US Food and Drug Administration’s IND reform pilot program (11:22), including the potentially influential role of external qualified research institutions (16:20) and the resources the pilot will require (20:29).

More On These Topics From The Pink Sheet

Oncology Overlap, Nationalism Cast Doubts On Potential AstraZeneca/BMS Merger: insights.citeline.com/pink-sheet/policy-regula…

Merged AstraZeneca, BMS Would Have Deep Solid Tumor And Blood Cancer Portfolio: insights.citeline.com/pink-sheet/r-and-d/merge…

US FDA’s IND Reform Pilot Could Use External Partners To Speed Trial Set-Up: insights.citeline.com/pink-sheet/r-and-d/clini…